Update from BP couple of wee snips
"OPT-302 moves up in the wet-AMD pecking order We expect Opthea with its drug OPT-302 to be a likely beneficiary of peer US based Opthotech’s setback on failure of its lead drug Fovista (anti-PDGF) in Phase 3 trials. Of the emerging wet-AMD therapies the anti-PDGF agents were garnering the most attention and were the most advanced. Fovista’s failure in the Phase 3 trials, coupled with the Phase 2 failure of Regeneron’s anti-VEGF/PDGF co-formulation rinucumab likely signals an end to the PDGF approach. This consequently moves OPT-302 up in the pecking order of drugs in development for wet AMD and therefore increases its attractiveness. OPT-302 which is targeting VEGF-C/D is now one of 2 potential combination targets with anti-VEGF in advanced development. We believe scarcity has value and as a consequence expect increased interest in the asset from the key players in the wet AMD market. "
and
"Valuation lifted by 16% to $0.95, Retain Buy "
- Forums
- ASX - By Stock
- OPT
- really really good
really really good, page-9
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
47.5¢ |
Change
-0.020(4.04%) |
Mkt cap ! $584.7M |
Open | High | Low | Value | Volume |
49.5¢ | 50.8¢ | 47.5¢ | $4.304M | 9.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 29597 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 15044 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 27497 | 0.475 |
4 | 69173 | 0.470 |
1 | 15044 | 0.465 |
1 | 18645 | 0.460 |
3 | 20931 | 0.455 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 15044 | 2 |
0.490 | 15044 | 1 |
0.500 | 1540 | 1 |
0.505 | 1970 | 1 |
0.510 | 66230 | 3 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online